Timolol Maleate Ophthalmic Solution, 0.5%

DRUG6 trials

Sponsors

Alcon Research, Glaukos Corporation, SpyGlass Pharma, Inc.

Conditions

CataractGlaucomaGlaucoma Open-angleOcular HypertensionOpen Angle GlaucomaOpen-angle Glaucoma

Phase 1

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

Active, not recruitingNCT06120842

SpyGlass Pharma, Inc.Cataract, Glaucoma, Ocular Hypertension

Start: 2023-10-13End: 2027-11-30Updated: 2025-08-22

Phase 2

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

CompletedNCT02754596

Glaukos CorporationGlaucoma Open-angle

Start: 2016-03-29End: 2020-07-21Updated: 2023-09-26

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Glaukos CorporationOcular Hypertension, Open Angle Glaucoma

Start: 2023-11-15End: 2024-08-31Target: 250Updated: 2023-12-06

Phase 3

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

CompletedNCT00465803

Alcon ResearchOcular Hypertension, Open-angle Glaucoma

Start: 2007-03-31Updated: 2014-07-24

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

RecruitingNCT07218783

SpyGlass Pharma, Inc.Cataract, Glaucoma, Ocular Hypertension

Start: 2025-10-15End: 2031-03-31Target: 400Updated: 2025-10-20

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

RecruitingNCT07218796

SpyGlass Pharma, Inc.Cataract, Glaucoma, Ocular Hypertension

Start: 2025-10-28End: 2031-05-31Target: 400Updated: 2025-10-20

Related Papers

Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.

2023-12-0718 citations